Quick Answer
CytomX Therapeutics, Inc. reported Total Assets of $151.57 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed an increase of +25.7% in Total Assets from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $124.78 million | Q1 2016: $191.95 million | Q2 2016: $206.86 million | Q3 2016: $192.88 million | Q1 2017: $177.88 million | Q2 2017: $351.86 million | Q3 2017: $387.04 million | Q1 2018: $376.46 million | Q2 2018: $376.94 million | Q3 2018: $482.73 million | Q1 2019: $444.51 million | Q2 2019: $405.28 million | Q3 2019: $372.54 million | Q1 2020: $436.66 million | Q2 2020: $402.48 million | Q3 2020: $375.18 million | Q1 2021: $434.16 million | Q2 2021: $402.44 million | Q3 2021: $371.23 million | Q1 2022: $296.83 million | Q2 2022: $260.09 million | Q3 2022: $226.49 million | Q1 2023: $234.63 million | Q2 2023: $209.19 million | Q3 2023: $221.17 million | Q1 2024: $184.69 million | Q2 2024: $159.22 million | Q3 2024: $138.98 million | Q1 2025: $98.50 million | Q2 2025: $175.06 million | Q3 2025: $158.25 million.
- Over the full 12 years of available data (2014 to 2025), CytomX Therapeutics, Inc.'s Total Assets has grown by 107.4%.
- Historical annual values: Fiscal year 2025: $151.57 million | Fiscal year 2024: $120.53 million | Fiscal year 2023: $201.79 million | Fiscal year 2022: $260.89 million | Fiscal year 2021: $339.41 million | Fiscal year 2020: $358.66 million | Fiscal year 2019: $341.28 million | Fiscal year 2018: $457.11 million | Fiscal year 2017: $397.64 million | Fiscal year 2016: $199.13 million | Fiscal year 2015: $197.22 million | Fiscal year 2014: $73.06 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: